Aptahem AB (publ) (NGM:APTA)
Sweden · Delayed Price · Currency is SEK 0.7120
0.00 (0.00%)
At close: Apr 7, 2026
Aptahem AB Company Description
Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden.
The company’s lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions.
It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage.
The company has a collaboration with Hongene Biotech for the manufacturing of RNA and oligonucleotides.
Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Aptahem AB (publ)
| Country | Sweden |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Mikael Lindstam |
Contact Details
Address: Medeon Science Park Malmö, 205 12 Sweden | |
| Phone | 46 7 66 33 36 99 |
| Website | aptahem.com |
Stock Details
| Ticker Symbol | APTA |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mikael Lindstam | Co-Founder and Chief Executive Officer |
| Dr. Bert Junno | Co-Founder and Chairman |
| Dr. Kjell G. Stenberg | Chief Marketing Officer and Pres |
| Luiza Jedlina | Co-Founder and CSO |
| Ola Skanung | Chief Financial Officer |
| Maria Ekblad | Chief Operating Officer |
| Ulf Bjorklund M.Sc. | Senior Executive Advisor |
| Ingela Hallberg | Chief Medical Officer |